Innoviva Inc (INVA) Holdings Boosted by Jane Street Group LLC

Jane Street Group LLC grew its position in Innoviva Inc (NASDAQ:INVA) by 301.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,789 shares of the biotechnology company’s stock after purchasing an additional 30,619 shares during the quarter. Jane Street Group LLC’s holdings in Innoviva were worth $579,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of INVA. JPMorgan Chase & Co. boosted its position in shares of Innoviva by 1,379.9% in the third quarter. JPMorgan Chase & Co. now owns 780,546 shares of the biotechnology company’s stock worth $10,896,000 after purchasing an additional 727,803 shares during the period. Victory Capital Management Inc. boosted its position in shares of Innoviva by 5,441.8% in the fourth quarter. Victory Capital Management Inc. now owns 592,032 shares of the biotechnology company’s stock worth $8,401,000 after purchasing an additional 581,349 shares during the period. Renaissance Technologies LLC boosted its position in shares of Innoviva by 43.2% in the fourth quarter. Renaissance Technologies LLC now owns 1,518,900 shares of the biotechnology company’s stock worth $21,553,000 after purchasing an additional 458,520 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Innoviva by 22.4% in the third quarter. Dimensional Fund Advisors LP now owns 981,854 shares of the biotechnology company’s stock worth $13,864,000 after purchasing an additional 179,860 shares during the period. Finally, Old Mutual Global Investors UK Ltd. boosted its position in shares of Innoviva by 262.4% in the fourth quarter. Old Mutual Global Investors UK Ltd. now owns 179,600 shares of the biotechnology company’s stock worth $2,548,000 after purchasing an additional 130,043 shares during the period. Institutional investors and hedge funds own 74.99% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:INVA opened at $16.46 on Friday. The company has a debt-to-equity ratio of -2.37, a current ratio of 5.77 and a quick ratio of 5.77. Innoviva Inc has a fifty-two week low of $11.02 and a fifty-two week high of $17.21. The firm has a market cap of $1,698.42, a P/E ratio of 14.07 and a beta of 2.17.

Innoviva (NASDAQ:INVA) last issued its earnings results on Thursday, February 8th. The biotechnology company reported $0.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. Innoviva had a net margin of 61.76% and a negative return on equity of 48.93%. The firm had revenue of $69.52 million during the quarter, compared to analyst estimates of $67.41 million. During the same quarter in the prior year, the business earned $0.22 earnings per share. Innoviva’s revenue for the quarter was up 59.4% on a year-over-year basis. research analysts anticipate that Innoviva Inc will post 1.99 earnings per share for the current year.

In related news, VP George B. Abercrombie sold 8,000 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $16.51, for a total transaction of $132,080.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Desparbes sold 5,378 shares of the company’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $16.52, for a total transaction of $88,844.56. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

A number of equities analysts have weighed in on the stock. Stifel Nicolaus reiterated a “hold” rating and issued a $17.00 price target on shares of Innoviva in a research report on Friday, February 9th. BidaskClub upgraded shares of Innoviva from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 24th. ValuEngine upgraded shares of Innoviva from a “hold” rating to a “buy” rating in a research report on Wednesday, March 7th. TheStreet upgraded shares of Innoviva from a “c+” rating to a “b” rating in a research report on Friday, February 9th. Finally, Zacks Investment Research lowered shares of Innoviva from a “hold” rating to a “sell” rating in a research report on Saturday, February 3rd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $13.83.

ILLEGAL ACTIVITY WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3337394/innoviva-inc-inva-holdings-boosted-by-jane-street-group-llc.html.

About Innoviva

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

New Age Beverages  Stock Price Down 9.4% on Analyst Downgrade
New Age Beverages Stock Price Down 9.4% on Analyst Downgrade
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
BMO Capital Markets Increases Roots  Price Target to C$16.00
BMO Capital Markets Increases Roots Price Target to C$16.00
Syntel  Trading -0.6% Higher  After Strong Earnings
Syntel Trading -0.6% Higher After Strong Earnings
BNP Paribas Reiterates CHF 74 Price Target for Nestle
BNP Paribas Reiterates CHF 74 Price Target for Nestle
Roche  Given a CHF 230 Price Target at Morgan Stanley
Roche Given a CHF 230 Price Target at Morgan Stanley


Leave a Reply

© 2006-2018 Ticker Report. Google+.